2.1 CSA Schedules I–V & Illinois Alignment

2.1 CSA Schedules I–V & Illinois Alignment

Quick Answer: The federal Controlled Substances Act (CSA) sorts drugs into five schedules by accepted medical use, abuse potential, and dependence liability. Schedule I agents have no accepted medical use and cannot be prescribed. Schedules II–V may be prescribed under rules that loosen as the schedule number rises. Pharmacists share corresponding responsibility with the prescriber. The Illinois Controlled Substances Act (720 ILCS 570) tracks this framework, and the Illinois Prescription Monitoring Program (ILPMP) captures Schedules II–V (with limited exclusions such as testosterone per ILPMP guidance). On the Illinois MPJE, apply the more restrictive rule when state and federal standards differ.

Controlled-substance law is a major MPJE weight because almost every dispensing, ordering, inventory, and diversion scenario starts with one question: what schedule is the drug, and which federal floor applies? This section builds that foundation and ties it to Illinois so later chapters on prescribing, ILPMP, and operations make sense.

Why Scheduling Exists

Congress enacted the CSA (Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970) to create a closed system of distribution. Every controlled substance should move only among DEA-registered entities and, at the end of the chain, to a patient with a valid prescription (or under another lawful exception). Scheduling is the risk classification that drives:

• Whether a drug can be prescribed at all
• Whether DEA Form 222 / CSOS is required to order it
• Whether refills are allowed
• How tightly inventory counts and security must be applied
• How prescriptions and records must be filed

If you mis-schedule a drug on an exam vignette, every downstream answer about refills, partial fills, and ordering forms is likely wrong. Treat schedule as the first decision-tree branch.

The Five Federal Schedules

Schedule I (CI)

Schedule I substances have:

1. High potential for abuse
2. No currently accepted medical use in treatment in the United States
3. Lack of accepted safety for use under medical supervision

Classic examples include heroin, LSD, MDMA (ecstasy), peyote, and marijuana/cannabis under federal law. Even where Illinois has authorized medical or adult-use cannabis under state programs, federal Schedule I status is unchanged for CSA purposes. For the MPJE, remember: CI drugs are not prescribed or dispensed pursuant to a federal prescription. Research and certain authorized industrial uses exist under tight DEA control, but community-pharmacy practice does not lawfully stock CI for ordinary patient dispensing.

Schedule II (CII)

Schedule II substances have high abuse potential, currently accepted medical use (sometimes with severe restrictions), and abuse that may lead to severe psychological or physical dependence.

High-yield CII examples: morphine, oxycodone, hydrocodone combination products, hydromorphone, fentanyl, methadone, amphetamine, methylphenidate, cocaine (as a topical anesthetic), and certain combination products historically rescheduled into CII. CII drugs drive the strictest ordering (Form 222/CSOS), no federal refills, special partial-fill rules, and often the most careful security practices.

Schedule III (CIII)

Schedule III substances have abuse potential less than CI/CII, accepted medical use, and abuse that may lead to moderate or low physical dependence or high psychological dependence. Common examples: products containing limited codeine (for example, acetaminophen with codeine tablets at federal quantity limits), buprenorphine, ketamine, anabolic steroids, and certain barbiturate combinations. CIII prescriptions may be refilled under the federal 5-refill / 6-month ceiling (covered in depth in section 2.3).

Schedule IV (CIV)

Schedule IV substances have lower abuse potential relative to CIII, accepted medical use, and limited dependence liability relative to CIII. High-frequency exam drugs: benzodiazepines (alprazolam, diazepam, clonazepam, lorazepam), zolpidem and other Z-drugs, tramadol, carisoprodol, and phenobarbital. CIV follows the same federal refill framework as CIII (5 refills / 6 months).

Schedule V (CV)

Schedule V substances have the lowest abuse potential among controlled drugs, accepted medical use, and limited dependence relative to CIV. Examples include certain codeine-containing cough preparations within federal concentration limits, pregabalin, lacosamide, and other limited-quantity narcotic preparations. Federally, CV refill rules are more flexible than CIII/CIV (no automatic 5/6 hard cap), but Illinois reporting and practice rules still treat CV as controlled—never treat “Schedule V” as “not really controlled.”

How to Reason About an Unfamiliar Drug

Exam writers love obscure brand names. You rarely need the full FDA label. Use this pattern:

1. Is there accepted medical use? If not → think Schedule I (or not a drug for prescribing).
2. Is it a potent opioid agonist, stimulant, or high-risk pain/ADHD agent? → often CII.
3. Is it a benzodiazepine, Z-drug, tramadol, or carisoprodol? → often CIV.
4. Is it buprenorphine or a limited-codeine combo? → often CIII.
5. Is it a low-dose narcotic cough prep or certain anticonvulsants like pregabalin? → often CV.

When the stem gives the schedule, trust the stem—then apply the matching federal rule set.

Corresponding Responsibility

Under federal regulation (21 CFR 1306.04), a prescription for a controlled substance must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice. The responsibility for proper prescribing and dispensing is on the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription.

In plain language:

• The prescriber must not write CS prescriptions outside legitimate practice.
• The pharmacist must not knowingly dispense an invalid or illegitimate CS prescription.
• “The doctor wrote it” is not a complete defense if red flags made the order clearly improper and the pharmacist ignored them.

Corresponding responsibility bridges later Illinois red-flag and ILPMP chapters. On federal-foundation items, expect scenarios such as: early refill requests with no clinical explanation, cash-paying patients traveling long distances for high-dose opioids, identical “pain” scripts from a single clinic for many unrelated patients, or prescriptions that look altered. Your job is not to diagnose the patient—it is to decide whether the order can lawfully be dispensed as a valid CS prescription.

Practical pharmacist steps when legitimacy is in doubt:

• Verify the prescriber’s identity, DEA registration, and authority for the schedule involved
• Contact the prescriber for clinical clarification and document the conversation
• Check the ILPMP (required territory in Illinois practice—see chapter 10)
• Refuse to fill when the prescription is not for a legitimate medical purpose or is outside usual professional practice
• Never “partially comply” with an order you believe is forged or clearly diversionary just to avoid conflict

Illinois Alignment: 720 ILCS 570 and the ILPMP Overlay

Illinois’s controlled-substance framework lives primarily in 720 ILCS 570 (Illinois Controlled Substances Act), with pharmacy practice duties layered through 225 ILCS 85 and 68 Ill. Adm. Code 1330. For MPJE purposes, treat Illinois schedules as aligned with the federal CSA architecture: the same five-schedule logic, the same idea that CI is not for ordinary prescribing, and the same principle that CII is the most tightly controlled prescribed class.

Two Illinois overlays matter even in a “federal foundations” chapter:

1) Illinois may be stricter

NABP’s MPJE does not split “federal questions” from “state questions” on the score report. If Illinois imposes a tighter refill, reporting, security, e-prescribing, or prescribing rule than the federal floor, answer under prevailing Illinois law. Federal law is the baseline; Illinois is the jurisdiction that licenses you through IDFPR.

2) ILPMP reporting covers Schedules II–V

Under Illinois PMP rules, dispensers report controlled substances to the Illinois Prescription Monitoring Program (ILPMP). Exam-critical scope for foundations:

• Schedules II, III, IV, and V are generally reportable when dispensed
• ILPMP guidance excludes certain agents (notably testosterone per ILPMP site materials) and may list additional drugs of interest
• Expanded query expectations continue to evolve (including statutory changes effective 1/1/2027 under PA 104-0512)—later chapters drill operational query duties

That means a technically correct federal schedule answer can still produce a wrong PMP answer if you forget that Schedule V remains controlled and reportable in Illinois. Memorize the reporting scope now so it becomes automatic.

Scheduling Changes and “Who Decides?”

Federally, scheduling authority involves the DEA and scientific/medical evaluation processes (with HHS/FDA input under the CSA framework). States can schedule or control substances under state law as well. If a drug is controlled under Illinois law even when federal status is evolving, Illinois practice and IDFPR expectations still control your conduct as an Illinois pharmacist. Exam items may mention rescheduling of a product (for example, historical hydrocodone combination product movement into CII)—use the schedule stated in the vignette and apply current rule logic for that schedule.

Connecting Schedules to Later Federal Rules (Preview)

Keep this cheat-map in your head as you move through the rest of Chapter 2:

Exam Scenario: Chicago Community Pharmacy

A patient presents a handwritten prescription for “oxycodone 30 mg, #120, take 1 q6h prn pain, refill ×2” from an out-of-area clinic. The drug is CII. Even before Illinois e-prescribing and ILPMP chapters, you already know: federal law forbids CII refills, so the refill authorization is invalid on its face. You still must assess legitimacy, verify the prescriber, and apply Illinois rules—but the schedule alone killed the refill language.

Common Traps

• Treating cannabis as “not controlled” because Illinois has adult-use markets—federal CI remains CI for CSA exam logic
• Confusing CIII vs CIV refill ceilings (they share the same federal 5/6 framework)
• Assuming Schedule V means “no PMP and no pharmacist scrutiny”
• Answering only with the federal floor when an Illinois vignette states a stricter duty
• Forgetting corresponding responsibility when the stem screams red flags

Master the five schedules, corresponding responsibility, and the Illinois more-restrictive-wins rule. Everything else in Chapter 2 hangs on those three anchors.